TheEdgeResearch
Home / Stocks / YDES

YD Bio Limited Ordinary Shares (YDES)

NASDAQ Healthcare Biotechnology
$2.65 ▼ -16.93%
Market Cap
$187.7M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.12
52-Wk Range
1.7-22
CEO
Ethan Shen
Country
TW
Currency
USD

YD Bio Limited Ordinary Shares operates in the Biotechnology industry of the Healthcare sector, headquartered in Taipei, TP, TW. The stock last traded at $2.65, down 16.93% on the session, giving a market capitalisation of $187.7M. On trailing twelve-month figures it carries a trailing P/E of -1.63, a net margin of 0.0%. Its beta of -0.12 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.63
Price / Sales
0.00
Price / Book
2.02
EV / EBITDA
-33.15
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.00
Current ratio
5.23
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
15
IPO date
2025-08-29
Headquarters
Taipei, TP, TW
About YD Bio Limited Ordinary Shares

Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.

Comparable companies

YD Bio Limited Ordinary Shares is most often compared with the following Healthcare names:

BTXDAWNGERNGLUELENZMRVIPRMETBPHTYRAVIR
More research on YDES
YDES technical analysis YDES TheEdge Score Compare against peers
Open full interactive analysis & DCF →